CTOs on the Move


 
Qvella is a molecular diagnostics company with the goal of dramatically reducing time to results in bacteriology. The company has developed a highly differentiated technology for pathogen detection by direct sampling of boldily fluids without the need for culturing or time consuming sample processing.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.qvella.com
  • 9133 Leslie Street Unit 110
    Richmond Hill, ON CAN L4B 4N1
  • Phone: 289.317.0550

Executives

Name Title Contact Details

Funding

Qvella raised $20M on 10/29/2015

Similar Companies

TVA Medical

TVA Medical, Inc. is a medical device company developing innovative, minimally invasive therapies for treatment of End-Stage Renal Disease (ESRD). The company was founded by Dr. William Cohn in partnership with Sante Ventures, a life sciences venture capital firm based in Austin, TX.

MLS Logistics

MLS Logistics is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

www.biosig.com

BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.

Accelmed Growth Partners

Accelmed is an investment firm focused on value creation for medical device companies and technologies. Accelmed was founded in 2009 by Mori Arkin and Uri Geiger and invests in small and mid-cap private and public companies.

RIEMSER

RIEMSER is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.